natgillin/translations-raw huggingface dataset:
A method in a sending node (110) for handling status information of data units or data unit segments "data units" transmitted from the sending node (110) to the receiving node (120) over a radio link (130), the method comprising the steps of: 
Postupak u čvoru pošiljatelju (110) za upravljanje statusnim informacija o podatkovnim jedinicama koje odašilje čvor pošiljatelj (110) u čvor primatelj (120) preko radio veze (130), a postupak obuhvaća korake:
Method according to claim 4, wherein the negative acknowledgement for the first part (2,3,4) of missing data units comprised in the reduced status message is represented by as many negative acknowledgements as fitted in the reduced status message because of limited resources. 
Postupak prema zahtjevu 4, gdje je negativna potvrda za prvi dio (2,3,4) podatkovnih jedinica koje nedostaju, a koja je sadržana u reduciranoj poruci o statusu, predstavljena s toliko negativnih potvrda koliko stane u reduciranu poruku o statusu zbog ograničenih resursa.
Method according to any of the claims 9-10, wherein the negative acknowledgement for the fist part (2,3,4) of missing data units are the missing data units which are closest to a lower edge of a receiving window in the receiving node (120). 
Postupak prema bilo kojem od zahtjeva 4-5 gdje je negativna potvrda za prvi dio (2,3,4) podatkovnih jedinica koje nedostaju za one podatkovne jedinice koje nedostaju, a koje su najbliže donjem rubu okvira primanja u čvorovima primateljima (120).
Rb is selected from the group consisting of hydrogen, alkyl and alkylcarbonyl; Rc is alkyl; 
Rb je odabran iz skupine koju čine vodik, alkil i alkilkarbonil; Rc je alkil;
Use of a therapeutically effective amount of a compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt, ester or amide thereof, in the manufacture of a medicament for selectively modulating the effects of a nicotinic acetylcholine receptors, a4β2 nicotinic acetylcholine receptors, or both a and a4β2 nicotinic acetylcholine receptors. 
Uporaba terapijski učinkovite količine spoja iz bilo kojeg patentnog zahtjeva 1 do 7 ili njegove farmaceutski prihvatljive soli, naznačena time, da se koristi za proizvodnju lijeka za selektivnu modulaciju učinaka a nikotinskih acetilkolinskih receptora, a4p2 nikotinskih acetilkolinskih receptora ili a i a4p2 nikotinskih acetilkolinskih receptora zajedno.
Use of a compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt, ester or amide thereof, in the manufacture of a medicament for treating or preventing a condition or disorder selected from the group consisting of a cognitive disorder, neurodegeneration, schizophrenia, and cognitive deficits of schizophrenia. 
Uporaba spoja iz bilo kojeg patentnog zahtjeva 1 do 7 ili njegove farmaceutski prihvatljiva soli, naznačena time, da se koristi za proizvodnju lijeka za liječenje ili sprječavanje stanja ili poremećaja odabranih iz skupine koju čine: kognitivni poremećaj, neurodegeneracija, schizophrenia i kognitivni deficit povezan sa schizophrenijom.
A method for controlling a hemipteran pest, comprising applying an effective amount of a compound represented by formula (Ia) according to claim 1, or an agriculturally and horticulturally acceptable salt thereof to a plant or soil. 
Metoda za kontrolu štetočina, naznačena time da obuhvaća primjenu učinkovite količine spoja predstavljenim formulom (Ib) prema patentnom zahtjevu 1 ili agrikulturno ili hortikulturno prihvatljivu sol na zemlji ili na biljci.
A crystalline form of a compound of Formula (A): which is designated Form II, wherein the X-ray diffraction pattern comprises peaks at (± 0.15 degrees 2 theta): 5.71 degrees, 11.47 and 9.97 degrees 2-theta, wherein XRPD patterns were obtained with a X-ray powder diffractometer using K-alpha radiation and samples were scanned at a rate of 1.0 degree/minute from 2 to 40 degrees in angle 2-theta. 
Kristalni oblik spoja Formule (A): [image] označen kao Oblik II, naznačen time što mu uzorak difrakcije rendgenskih zraka sadrži pikove na (± 0,15° 2θ): 5.71°, 11,47 i 9,97° 2θ, gdje su uzorci XRPD dobiveni difraktometrom rendgenskih zraka na prahu, uz pomoć zračenja Ka, a uzorci su skenirani brzinom od 1,0° u minuti, od 2 do 40°, pod uglom od 2θ.
A process of preparing the crystalline form of claim 1, said process comprising the steps of mixing 7-chloro- N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4 H -pyridazino[4,5-b]indole-1-acetamide with a lower alcohol, for example methanol or ethanol, at a concentration of about 1 mg/ml to about 4 mg/ml to form a mixture, heating the mixture to a temperature between about 45°C and about 60 °C; filtering the mixture, and evaporating the lower alcohol in the filtrate with a stream of inert gas to form a solid. 
Postupak dobivanja kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u koracima miješanja 7-klor-N,N,5-trimetil-4-okso-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida s nižim alkoholom, primjerice metanolom ili etanolom, u koncentraciji od otprilike 1 mg/ml do otprilike 4 mg/ml, kako bi se dobilo smjesu, grijanja smjese do temperature između otprilike 45 °C i otprilike 60 °C, filtriranja smjese, te otparavanja nižeg alkohola iz filtrata strujom inertnog plina kako bi se dobilo krutinu.
A process of preparing the crystalline form of claim 1, said process comprising the steps of dissolving 7-chloro- N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4 H -pyridazino[4,5-b]indole-1-acetamide in dichloromethane at a concentration of about 30 mg/ml to about 50 mg/ml to form a solution; adding the solution to ethanol at a ratio of about 1:3 to about 1:4 by volume relative to the amount of dichloromethane; concentrating the solution, reducing the volume by about 10% to about 40%, with a stream of inert gas until a solid crystallizes; and isolating the solid. 
Postupak dobivanja kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u koracima otapanja 7-klor-N,N,5-trimetil-4-okso-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida u diklormetanu, u koncentraciji od otprilike 30 mg/ml do otprilike 50 mg/ml, kako bi se dobilo otopinu; dodavanja otopine u etanol, u omjeru od otprilike 1:3 do otprilike 1:4, volumno, u odnosu na količinu diklormetana, zatim koncentriranja otopine, smanjivanja volumena za otprilike 10% do otprilike 40% strujom inertnog plina dok se krutina ne iskristalizira, te izdvajanja krutine.
A process for the preparation of a compound as claimed in any of claims 1 to 6, or a physiologically acceptable salt thereof, in which A is -Y-CH2-CH2- (formula Ib), comprising reacting a compound of the formula IV and compound of the formula V, wherein Het, X, Y, R1, R2 and R3 are defined as in claims 1 to 6 and, in addition, any functional groups can be present in protected form or in the form of precursor groups, and L1 is a nucleophilically substitutable leaving group. 
Postupak dobivanja spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili njegove fiziološki prihvatljive soli, gdje A je -Y-CH2-CH2- (spoj formule Ib), naznačen time što se sastoji u reakciji spoja formule IV sa spojem formule V, [image] gdje su Het, X, Y, R1, R2 i R3 definirani kao u patentnim zahtjevima 1 do 9, gdje, uz to, sve funkcionalne skupine mogu biti prisutne u zaštićenom obliku ili u obliku prekursorske skupine, a L1 se može nukleofilno supstituirati izlaznom skupinom.
Use of tapentadol for the manufacture of a medicament comprising 
Tapentadol za upotrebu u liječenju boli, naznačen time da se
at least one administration unit A containing dose a of tapentadol and 
najmanje jednu jedinicu za davanje A koja sadrži dozu a tapentadola i
The use according to claim 3, where dose a is within the range of from 10 to 65 wt.-% of dose c and where dose b is within the range of from 35 to 90 wt.-% of dose c . 
Lijek prema patentnom zahtjevu 10, naznačen time da je doza a unutar raspona od 10 do 65 % po težini doze c i da je doza b unutar raspona od 35 do 90 % po težini doze c.
A packaging according to claim 4, characterized in that neighbouring bars (7) are interconnected by means of at least two, and preferably three, separate ribs (8) that are thinner than the bars (7) in the normal direction to the plane of the pull tab (5). 
Spremnik prema bilo kojem od prethodnih zahtjeva, naznačen time što su susjedne prečke (7) međusobno povezane preko barem dvije, poželjno tri, odvojene prečke (8) koje su uže od prečki (7) u smjeru normalnom prema ravnini jezička za povlačenje (5).
n is an integer from one to six; 
naznačen time što n je jedan;
The pharmaceutical composition of claim 3, characterized in that the total weight of the drug impurities is not more than 0.3 percent of the weight of the compound imiquimod. 
Farmaceutski pripravak iz patentnog zahtjeva 3, naznačen time, da ukupna težina nečistoća u lijeku nije veća od 0,3 posto težinskog udjela spoja imikvimoda.
The pharmaceutical composition of claim 8 characterized in that the preservative is selected from the group consisting of methylparaben, propylparaben, benzyl alcohol, and mixtures thereof. 
Farmaceutski pripravak iz patentnog zahtjeva 8, naznačen time, da je konzervans odabran iz skupine koju čine: metilparaben, propilparaben, benzil alkohol i njihove smjese.
The packaged composition of claim 14, characterized in that the packaging material is a multi-layer laminate. 
Pakirani pripravak iz patentnog zahtjeva 14, naznačen time, da je materijal za pakiranje višeslojni laminat.
The packaged composition of any one of claims 14 to 18 characterized in that the packaging material is in the form of a single-use sachet. 
Pakirani pripravak iz bilo kojeg od patentnih zahtjeva 14 do 18, naznačen time, da je materijal za pakiranje u obliku vrećice za jednokratnu uporabu.
The packaged composition of claim 20, characterized in that the packaging material is a tube. 
Pakirani pripravak iz patentnog zahtjeva 20, naznačen time, da je materijal za pakiranje tuba.
The method of claim 27 characterized in that the sterility assurance level is 10-6. 
Postupak iz patentnog zahtjeva 27, naznačen time, da zajamčena razina steriliziranosti iznosi 10-6.
The method of claim 27 or claim 28, characterized in that the sterilizing dose is at least 25 kGy. 
Postupak iz patentnog zahtjeva 27 ili iz patentnog zahtjeva 28, naznačen time, da doza za steriliziranje iznosi najmanje 25 kGy.
A dry dock according to Claim 8 wherein the platform is of generally rectangular shape and one link of each pair of links is provided at a corner of the platform and the other link of each pair of links is provided at a respective opposite corner or the platform. 
Suhi dok u skladu s patentnim zahtjevom 8, naznačen time što platforma ima općenito pravokutan oblik i jedan spojni element od svakog para spojnih elemenata je predviđen na uglu platforme, a drugi spojni element svakog para spojnih elemenata je predviđen na odgovarajućem suprotnom uglu platforme.
A humanized anti-beta7 antibody comprising: 
Humanizirano anti-beta7 protutijelo, naznačeno time, da obuhvaća:
The humanized anti-beta7 antibody of claim any one of the preceding claims, wherein the anti-beta7 antibody comprises one or more human and/or human consensus framework sequences in its heavy and/or light chain variable domain. 
Humanizirano anti-beta7 protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time, da anti-beta7 protutijelo obuhvaća jednu ili više humanih sekvenci i/ili humanih okvira konsenzualnih sekvenci u svojoj varijabilnoj domeni jakog i/ili slabog lanca.
The humanized anti-beta7 antibody of any one of claims 9 to 11, wherein the amino acid at heavy chain framework position 71 is selected from the group of R, A, and T, and/or the amino acid at heavy chain framework position 73 is selected from the group consisting of N and T, and/or the amino acid at heavy chain position 78 is selected from the group consisting of F, A, and L. 
Humanizirano anti-beta7 protutijelo prema bilo kojem zahtjevu 9 do 11, naznačeno time, da je amino kiselina na poziciji 71 okvira jakog lanca odabrana iz skupine koju čine R, A, i T, i/ili je amino kiselina na poziciji 73 okvira jakog lanca odabrana iz skupine koju čine N i T, i/ili je amino kiselina na poziciji 78 jakog lanca odabrana iz skupine koju čine F, A, i L.
The humanized antibody or binding fragment thereof of claim 15, wherein the affinity is at least 2-fold, at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1000-fold, at least 5000-fold, or at least 10,000-fold greater than an antibody comprising light chain and heavy chain sequences depicted in Fig. 1A SEQ ID NO:10 and Fig. 1B SEQ ID NO:11, or Fig. 9A SEQ ID NO:12 and Fig. 9B SEQ ID NO:13. 
Humanizirano protutijelo ili njegov vezni fragment prema zahtjevu 15, naznačeno time, da je njegov afinitet najmanje 2-nabora, najmanje 5-nabora, najmanje 10-nabora, najmanje 50-nabora, najmanje 100-nabora, najmanje 500-nabora, najmanje 1000-nabora, najmanje 5000-nabora, ili najmanje 10.000-nabora veći nego od protutijela koje obuhvaća sekvence slabog lanca i jakog lanca opisane u slici 1A kao SEQ ID NO:10 i u slici 1B kao SEQ ID NO:11, ili u slici 9A kao SEQ ID NO:12 i u slici 9B kao SEQ ID NO:13.
The humanized antibody or binding fragment of claim 10, wherein monovalent affinity of the antibody to human beta7 is at least 3-fold greater than monovalent affinity of an antibody comprising light chain and heavy chain sequences depicted in Fig. 1A (SEQ ID NO:10) and Fig. 1B (SEQ ID NO:11), or Fig. 9A (SEQ ID NO:12) and Fig. 9B (SEQ ID NO:13). 
Humanizirano protutijelo ili vezni fragment prema zahtjevu 16, naznačeno time, da je monovalentni afinitet protutijela prema humanom beta7 najmanje 3-nabora veći nego monovalentni afinitet protutijela koje obuhvaća sekvence slabog lanca i jakog lanca opisane u slici 1A kao SEQ ID NO:10 i u slici 1B kao SEQ ID NO:11, ili u slici 9A kao SEQ ID NO:12 i u slici 9B kao SEQ ID NO:13.
The humanized antibody or binding fragment of claim 15, wherein the binding affinity is measured by Biacore™ or radioimmunoassay. 
Humanizirano protutijelo ili vezni fragment prema zahtjevu 15, naznačeno time, da je afinitet vezanja izmjeren pomoću BiacoreTM ili radioimuno ispitivanjem.
The humanized anti-beta7 antibody of any one of claims 9 to 14, wherein the monovalent affinity of the antibody to human beta7 is substantially the same as or greater than the monovalent affinity to human beta7 of an antibody comprising light chain and heavy chain variable sequences as depicted in Fig. 1A SEQ ID NO:10 and/or Fig. 1B SEQ ID NO:11, or Fig. 9A SEQ ID NO:12 and/or Fig. 9B SEQ ID NO:13. 
Humanizirano anti-beta7 protutijelo prema bilo kojem zahtjevu 9 do 14, naznačeno time, da je monovalentni afinitet protutijela prema humanom beta7 uglavnom isti ili veći nego monovalentni afinitet prema humanom beta7 od protutijela koje obuhvaća varijabilne sekvence slabog lanca i jakog lanca opisane u slici 1A kao SEQ ID NO:10 i/ili u slici 1B kao SEQ ID NO:11, ili u slici 9A kao SEQ ID NO:12 i/ili u slici 9B kao SEQ ID NO:13.
An anti-beta7 antibody according to any one of claims 1 to 21 for use in a method of inhibiting the interaction of a human beta7 integrin subunit with a second integrin subunit and/or a ligand by contacting with the beta7 integrin, wherein the inhibiting reduces or alleviates symptoms of a disorder selected from the group consisting of inflammation, asthma, inflammatory bowel disease, Crohn's disease, ulcerative colitis, diabetes, inflammation resulting of organ transplantation, graft versus host disorder, and inflammation associated with allograft disorders. 
Anti-beta7 protutijelo prema bilo kojem zahtjevu 1 do 21, naznačeno time, da se koristi u postupku inhibiranja interakcije humane beta7 integrinske podjedinice s drugom integrinskom podjedinicom i/ili s ligandom, stupanjem u vezu s beta7 integrinom, pri čemu inhibiranje smanjuje ili olakšava simptome poremećaja odabranih iz skupine koju čine upala, astma, upalna bolest crijeva, Chron-ova bolest, ulcerativni kolitis, dijabetes, zapaljenje kao rezultat transplantacije organa, bolest stanice domaćina zbog odbijanja presadaka, i upala povezana s poremećajima kod alotransplantacije.
Use of an anti-beta7 antibody according to any one of claims 1 to 21 for the preparation of a medicament for use in a method of inhibiting the interaction of a human beta7 integrin subunit with a second integrin subunit and/or a ligand by contacting with the beta7 integrin, wherein the inhibiting reduces or alleviates symptoms of a disorder selected from the group consisting of inflammation, asthma, inflammatory bowel disease, Crohn's disease, ulcerative colitis, diabetes, inflammation resulting of organ transplantation, graft versus host disorder, and inflammation associated with allograft disorders. 
Uporaba anti-beta7 protutijela prema bilo kojem zahtjevu 1 do 21, naznačena time, da je za pripravljanje lijeka koji se koristi u postupku inhibiranja interakcije humane beta7 integrinske podjedinice s drugom integrinskom podjedinicom i/ili s ligandom, stupanjem u vezu s beta7 integrinom, pri čemu inhibiranje smanjuje ili olakšava simptome poremećaja odabranih iz skupine koju čine upala, astma, upalna bolest crijeva, Chron-ova bolest, ulcerativni kolitis, dijabetes, zapaljenje kao rezultat transplantacije organa, bolest stanice domaćina zbog odbijanja presadaka, i upala povezana s poremećajima kod alotransplantacije.
Use of a composition comprising an anti-beta7 antibody according to any one of claims 1 to 21 and a pharmaceutical carrier for the preparation of a medicament for use in a method of modulating beta7 integrin-mediated cellular adhesion and/or recruitment in a mammal experiencing a disorder; wherein the disorder is selected from the group consisting of inflammation, asthma, inflammatory bowel disease, Crohn's disease, ulcerative colitis, diabetes, inflammation resulting of organ transplantation, graft versus host disorder, and inflammation associated with allograft disorders. 
Uporaba sastava koji sadrži anti-beta7 protutijelo prema bilo kojem zahtjevu 1 do 21 i farmaceutski nosač, naznačena time, da je za pripravljanje lijeka koji se koristi u postupku moduliranja stanične adhezije posredovane beta7 integrinom i/ili okrepljenja sisavaca koji pate od poremećaja; pri čemu je poremećaj odabran iz skupine koju čine upala, astma, upalna bolest crijeva, Chron-ova bolest, ulcerativni kolitis, dijabetes, zapaljenje kao rezultat transplantacije organa, bolest stanice domaćina zbog odbijanja presadaka, i upala povezana s poremećajima kod alotransplantacije.
The use of any one of claims 34 or 35, wherein the composition further comprises a second biopharmaceutical agent or chemotherapeutic agent. 
Uporaba prema zahtjevu 34 ili 35, naznačena time, da sastav nadalje obuhvaća drugo biofarmaceutsko sredstvo ili kemoterapeutsko sredstvo.
A composition comprising a humanized anti-beta7 antibody according to any one of claims 1 to 21 and a pharmaceutically acceptable carrier. 
Sastav, naznačen time, da obuhvaća humanizirano anti-beta7 protutijelo prema bilo kojem zahtjevu 1 do 21 i farmaceutski prihvatljiv nosač.
A composition comprising an anti-beta7 antibody according to any one of claims 1 to 21 and a pharmaceutical carrier for use in a method of modulating beta7 integrin-mediated cellular adhesion and/or recruitment in a mammal experiencing a disorder; wherein the disorder is selected from the group consisting of inflammation, asthma, inflammatory bowel disease, Crohn's disease, ulcerative colitis, diabetes, inflammation resulting of organ transplantation, graft versus host disorder, and inflammation associated with allograft disorders. 
Sastav, naznačen time, da obuhvaća humanizirano anti-beta7 protutijelo prema bilo kojem zahtjevu 1 do 21 i farmaceutski prihvatljiv nosač za uporabu u postupku moduliranja stanične adhezije posredovane beta7 integrinom i/ili okrepljenja sisavaca koji pate od poremećaja; pri čemu je poremećaj odabran iz skupine koju čine upala, astma, upalna bolest crijeva, Chron-ova bolest, ulcerativni kolitis, dijabetes, zapaljenje kao rezultat transplantacije organa, bolest stanice domaćina zbog odbijanja presadaka, i upala povezana s poremećajima kod alotransplantacije.
The composition of claim 39, wherein the mammal is a human. claim 
Sastav prema zahtjevu 39, naznačen time, da sisavac je čovjek.
The composition of claim 39, wherein the composition further comprises a second biopharmaceutical agent or chemotherapeutic agent. 
Sastav prema zahtjevu 39, naznačen time, da sastav nadalje obuhvaća drugo biofarmaceutsko sredstvo ili kemoterapeutsko sredstvo.
Ar is a monocyclic, bicyclic or tricyclic aryl or heteroaryl ring system; 
Ar je monociklički, biciklički ili triciklički arilni ili heteroarilni prstenski sustav;
The process according to claim 15, wherein R3a is t-butoxycarbonyl, benzyloxycarbonyl, substituted benzyloxycarbonyl or fluorenylmethoxycarbonyl; or wherein R3X is an acid chloride, an acid anhydride, an activated ester, a chloroformate or a carbamic chloride. 
Postupak u skladu s patentnim zahtjevom 15, naznačen time, da R3a je t-butoksikarbonil, benziloksikarbonil, supstituirani benziloksikarbonil ili fluorenilmetoksikarbonil; ili kada je R3X kiselinski klorid, kiselinski anhidrid, aktivirani ester, kloroformat ili karbamin-klorid.
The process according to claim 18, which further comprises reacting the 4-unsubstituted-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine to with a compound of formula X-CH2-COOR' wherein X is a halogen and R' is an alkyl to form an ester compound of formula: and hydrolyzing the ester to form a compound of formula: 
Postupak u skladu s patentnim zahtjevom 18, naznačen time, da dodatno uključuje reakciju 4-nesupstituirani-2,3,4,5-tetrahidrobenzo[f][1,4]tiazepina sa spojem formule X-CH2-COOR’, u kojem je X halogen i R’ je alkil, čime se dobiva esterni spoj formule: [image] te hidrolizu estera, čime se dobiva spoj formule:
The process according to claim 24, wherein LG is a halogen or a sulfonate, the base is an alkali metal hydride, hydroxide or carbonate, pyridine or a trialkylamine and R3X is an acid chloride, an acid anhydride, an activated ester, a chloroformate or a carbamic chloride; wherein the sulfonate is selected from the group consisting of methanesulfonate, toluenesulfonate, benzenesulfonate, trifluoromethanesulfonate, nitrophenylsulfonate and bromophenylsulfonate, and wherein the halogen is selected from the group consisting of chloro, iodo and bromo. 
Postupak u skladu s patentnim zahtjevom 24, naznačen time, da LG je halogen ili sulfonat, baza je hidrid, hidroksid ili karbonat alkalijskog metala, piridina ili trialkilamin, a R3X je kiselinski klorid, kiselinski anhidrid, aktivirani ester, kloroformat ili karbamin-klorid; pri čemu je sulfonat odabran iz skupine koju čine: metansulfonat, toluensulfonat, benzensulfonat, trifluormetansulfonat, nitrofenilsulfonat i bromofenilsulfonat, a halogen je odabran iz skupine koju čine: kloro, jodo i bromo.
The process according to claim 26, wherein LG is a halogen or a sulfonate and the base is an alkali metal hydride, hydroxide or carbonate, pyridine or a trialkylamine, wherein the sulfonate is selected from the group consisting of methanesulfonate, toluenesulfonate, benzenesulfonate, trifluoromethanesulfonate, nitrophenylsulfonate and bromophenylsulfonate, and wherein the halogen is selected from the group consisting of chloro, iodo and bromo. 
Postupak u skladu s patentnim zahtjevom 26, naznačen time, da LG je halogen ili sulfonat, a baza je hidrid, hidroksid ili karbonat alkalijskog metala, piridina ili trialkilamin, pri čemu je sulfonat odabran iz skupine koju čine: metansulfonat, toluensulfonat, benzensulfonat, trifluormetansulfonat, nitrofenilsulfonat i bromofenilsulfonat, a halogen je odabran iz skupine koju čine: kloro, jodo i bromo.
A hair brush (10) as set forth in claim 1 in which the shorter length bristles (12b) are shorter than the longer bristles (12a) by a uniform amount. 
Četka za kosu (10) u skladu s patentnim zahtjevom 1, naznačena time što su kraće čekinje (12b) kraće od duljih čekinja (12a) za ujednačenu vrijednost.